Core Viewpoint - The approval of the Blue Whale TM intracranial aneurysm embolization support frame marks a significant advancement in treatment options for intracranial aneurysms in China, enhancing the company's position in the high-end medical device market [1] Group 1: Company Developments - The company has been deeply engaged in the high-end medical device sector for many years, focusing on "precision treatment" and has established a comprehensive layout around three main areas: pathway management, structural heart disease, and heart failure [1] - The company has over 30 products in its high-end medical device portfolio, with 23 products approved for market in China under the pathway management category and 1 product approved for structural heart disease [1] - The company is actively advancing clinical registration for other products in China, with plans for phased and tiered launches of innovative products to drive stable growth in this business segment [1] Group 2: Global Expansion - The company is also expanding its global footprint in the field of cardiovascular precision interventional diagnosis and treatment, having established technical collaborations with clinical centers or R&D platforms in multiple countries including the USA, Canada, Germany, Italy, and Switzerland [1] - The company has successfully built a comprehensive "passive + active" innovative device platform, which is expected to enhance its capabilities in the global market [1] - With the ongoing implementation of its "Go Global" strategy, the company aims to develop this segment into a leading global platform for cardiovascular precision interventional diagnosis and treatment, further enhancing its overall value [1]